Organisation paid for research Program year 2025 Source: CMS Open Payments

Erg Holding Company, LLC

Neither a doctor nor a teaching hospital

Research payments

$3,043,190

121 payments

Through program year 2025, Erg Holding Company, LLC is reported as receiving $3,043,190 in research payments, across 121 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $197,229 4
2024 Research $459,198 10
2023 Research $188,450 5
2022 Research $1,828,562 52
2021 Research $18,522 1
2020 Research $13,251 2
2019 Research $337,979 47

Breakdown

Who paid Research payments · program years 2019–2025
  1. Genentech, Inc. $1,787,748 49 payments
  2. AstraZeneca UK Limited $568,854 10 payments
  3. AbbVie, Inc. $337,979 47 payments
  4. Agios Pharmaceuticals, Inc. $170,487 4 payments
  5. Sage Therapeutics, Inc. $100,927 4 payments
  6. Globus Medical, Inc. $54,065 5 payments
  7. Merck Sharp & Dohme Corporation $18,522 1 payment
  8. Alexion Pharmaceuticals, Inc. $4,608 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. Giredestrant Ddi $1,757,748 48 payments
  2. M15-566 $269,546 36 payments
  3. A Phase I Single-Dose Non-Randomised Open-Label Parallel Group Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics Safety and Tolerability of AZD0780 $236,513 4 payments
  4. Ag348-C-024 $170,487 4 payments
  5. A SingleDose NonRandomised OpenLabel ParallelGroup Study to Investigate the Effects of Renal Impairment on the Pharmacokinetics Safety and Tolerability of Opemalirsen AZD2373 $134,944 1 payment
  6. A Phase I Single-Dose Non-Randomised Open-Label Parallel-Group Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics Safety and Tolerability of AZD0780 $113,931 2 payments
  7. A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Sage-718 in Participants With Mild Cognitive Impairment Or Mild Dementia Due to Alzheimer's Disease $90,277 3 payments
  8. a Phase I Single Dose Non Randomised OpenL abel Parallel Group Study to Investigate the Effect of Hepatic Impairment on the pharmacokinetics Safety, and Tolerability of Balcinrenone $83,467 3 payments
  9. M15-570 $68,433 11 payments
  10. Aminos RT $54,065 5 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record